Genopharm collapse throws doubt on product recalls and court cases
This article was originally published in Scrip
Executive Summary
France's regulatory body Afssaps has delayed a recall of all products marketed by Laboratoires Genopharm after the rare diseases firm was unexpectedly dissolved by its owners. Genopharm's operations and those of its French affiliate Alkopharm, to which its assets have been transferred, had been suspended in December pending a resolution of pharmacovigilance and other regulatory issues, and the phased recalls were due to start on 2 January.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.